Top-Rated StocksTop-RatedNASDAQ:PGNY Progyny (PGNY) Stock Price, News & Analysis → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free PGNY Stock Alerts $26.98 -0.35 (-1.28%) (As of 06/14/2024 08:51 PM ET) Add Compare Share Share Today's Range$26.85▼$27.3250-Day Range$26.30▼$35.9552-Week Range$23.90▼$44.95Volume843,300 shsAverage Volume940,554 shsMarket Capitalization$2.57 billionP/E Ratio44.23Dividend YieldN/APrice Target$43.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Progyny alerts: Email Address Progyny MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside59.8% Upside$43.11 Price TargetShort InterestBearish8.96% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.23Based on 6 Articles This WeekInsider TradingSelling Shares$3.85 M Sold Last QuarterProj. Earnings Growth10.96%From $0.73 to $0.81 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.28 out of 5 starsMedical Sector134th out of 913 stocksMiscellaneous Health & Allied Services, Not Elsewhere Classified Industry1st out of 8 stocks 4.5 Analyst's Opinion Consensus RatingProgyny has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageProgyny has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Progyny's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.96% of the float of Progyny has been sold short.Short Interest Ratio / Days to CoverProgyny has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Progyny has recently decreased by 3.54%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldProgyny does not currently pay a dividend.Dividend GrowthProgyny does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PGNY. Previous Next 3.5 News and Social Media Coverage News SentimentProgyny has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Progyny this week, compared to 4 articles on an average week.Search Interest3 people have searched for PGNY on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Progyny to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,853,985.00 in company stock.Percentage Held by Insiders12.30% of the stock of Progyny is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Progyny's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Progyny are expected to grow by 10.96% in the coming year, from $0.73 to $0.81 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Progyny is 44.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.03.Price to Earnings Ratio vs. SectorThe P/E ratio of Progyny is 44.23, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 138.90.Price to Earnings Growth RatioProgyny has a PEG Ratio of 1.75. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioProgyny has a P/B Ratio of 4.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Progyny's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad StocksToTradeWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution About Progyny Stock (NASDAQ:PGNY)Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.Read More PGNY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PGNY Stock News HeadlinesJune 11, 2024 | prnewswire.comFertility Pioneer and Kindbody Founder Gina Bartasi Returns as CEO to Lead Company's Next Phase of GrowthJune 10, 2024 | seekingalpha.comProgyny: At This Price, Secular Tailwinds Are Too Compelling To IgnoreJune 4, 2024 | globenewswire.comProgyny, Inc. to Present at Jefferies Global Healthcare ConferenceJune 3, 2024 | seekingalpha.comProgyny: No Change To Long-Term OutlookMay 22, 2024 | msn.comProgyny’s board approves another $100 million stock buybackMay 22, 2024 | globenewswire.comProgyny, Inc. Announces Additional Share Repurchase ProgramMay 14, 2024 | globenewswire.comProgyny, Inc. to Present at BofA Securities 2024 Healthcare Conference and Leerink Partners Healthcare Crossroads Conference 2024May 13, 2024 | finance.yahoo.comProgyny (NASDAQ:PGNY) Has More To Do To Multiply In Value Going ForwardMay 10, 2024 | msn.comProgyny’s stock plunges as demand for IVF treatments drops after Alabama rulingMay 10, 2024 | msn.comKeybanc Downgrades Progyny (PGNY)May 10, 2024 | markets.businessinsider.comFertility Solutions-Focused Progyny Stock Sinks After Soft Guidance; Analyst Says 'Can No Longer Underwrite Sustained Healthy Growth In Forecasts'May 10, 2024 | finance.yahoo.comProgyny Inc (PGNY) Q1 2024 Earnings: Mixed Results Amid Market ChallengesMay 10, 2024 | finance.yahoo.comProgyny, Inc. (NASDAQ:PGNY) Q1 2024 Earnings Call TranscriptMay 10, 2024 | investorplace.comWhy Is Progyny (PGNY) Stock Down 27% Today?May 10, 2024 | investorplace.comWhy Is Progyny (PGNY) Stock Down 27% Today?May 10, 2024 | marketwatch.comProgyny Shares Plunge After Sales Take Hit From Alabama Embryo RulingMay 9, 2024 | investorplace.comPGNY Stock Earnings: Progyny Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.comProgyny, Inc. Announces First Quarter 2024 ResultsMay 3, 2024 | finance.yahoo.comInsider Sale: President Michael Sturmer Sells Shares of Progyny Inc (PGNY)April 26, 2024 | nasdaq.comProgyny Rings the Nasdaq Stock Market Closing BellApril 26, 2024 | markets.businessinsider.comBarclays Keeps Their Buy Rating on Progyny (PGNY)April 25, 2024 | globenewswire.comProgyny, Inc. Announces Details for Its First Quarter 2024 Results ReportApril 20, 2024 | finance.yahoo.comProgyny, Inc. (PGNY)April 17, 2024 | finance.yahoo.comProgyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building CareApril 17, 2024 | globenewswire.comProgyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building CareSee More Headlines Receive PGNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/16/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:PGNY CUSIPN/A CIK1551306 Webwww.progyny.com Phone212-888-3124FaxN/AEmployees563Year Founded2008Price Target and Rating Average Stock Price Target$43.11 High Stock Price Target$57.00 Low Stock Price Target$30.00 Potential Upside/Downside+59.8%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$0.61 Trailing P/E Ratio44.23 Forward P/E Ratio36.96 P/E Growth1.75Net Income$62.04 million Net Margins5.53% Pretax Margin6.94% Return on Equity11.61% Return on Assets8.28% Debt Debt-to-Equity RatioN/A Current Ratio3.31 Quick Ratio3.31 Sales & Book Value Annual Sales$1.09 billion Price / Sales2.36 Cash Flow$0.67 per share Price / Cash Flow40.20 Book Value$5.77 per share Price / Book4.68Miscellaneous Outstanding Shares95,220,000Free Float83,509,000Market Cap$2.57 billion OptionableOptionable Beta1.46 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMr. David J. Schlanger (Age 65)Executive Chairman Comp: $513.57kMr. Peter Anevski (Age 57)CEO & Director Comp: $1.09MMr. Michael Sturmer (Age 47)President Comp: $836.49kMr. Mark S. Livingston (Age 58)Chief Financial Officer Comp: $749.56kMs. Allison Swartz (Age 34)Executive VP, General Counsel & Secretary Comp: $546.22kMr. Steven LeistChief Technology OfficerMr. James HartVice President of Investor RelationsMs. Risa FisherChief Marketing OfficerMs. Cassandra PrattChief Human Resources OfficerMs. Julie StadlbauerChief Business Development OfficerMore ExecutivesKey CompetitorsSotera HealthNASDAQ:SHCagilon healthNYSE:AGLTivity HealthNASDAQ:TVTYAmerican Renal AssociatesNYSE:ARAViemed HealthcareNASDAQ:VMDView All CompetitorsInsiders & InstitutionsDekaBank Deutsche GirozentraleSold 76,600 shares on 6/4/2024Ownership: 0.004%Cambridge Trust Co.Bought 2,500 shares on 5/30/2024Ownership: 0.003%Farallon Capital Management LLCBought 592,600 shares on 5/24/2024Ownership: 0.622%Cetera Advisors LLCBought 8,412 shares on 5/24/2024Ownership: 0.009%Comerica BankBought 3,428 shares on 5/17/2024Ownership: 0.071%View All Insider TransactionsView All Institutional Transactions PGNY Stock Analysis - Frequently Asked Questions Should I buy or sell Progyny stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PGNY shares. View PGNY analyst ratings or view top-rated stocks. What is Progyny's stock price target for 2024? 10 brokers have issued 1-year price objectives for Progyny's shares. Their PGNY share price targets range from $30.00 to $57.00. On average, they anticipate the company's share price to reach $43.11 in the next twelve months. This suggests a possible upside of 59.8% from the stock's current price. View analysts price targets for PGNY or view top-rated stocks among Wall Street analysts. How have PGNY shares performed in 2024? Progyny's stock was trading at $37.18 at the beginning of 2024. Since then, PGNY stock has decreased by 27.4% and is now trading at $26.98. View the best growth stocks for 2024 here. When is Progyny's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our PGNY earnings forecast. How were Progyny's earnings last quarter? Progyny, Inc. (NASDAQ:PGNY) announced its quarterly earnings results on Thursday, May, 9th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.03. The business had revenue of $278.08 million for the quarter, compared to analyst estimates of $289.41 million. Progyny had a trailing twelve-month return on equity of 11.61% and a net margin of 5.53%. The firm's quarterly revenue was up 7.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.18 EPS. What ETFs hold Progyny's stock? ETFs with the largest weight of Progyny (NASDAQ:PGNY) stock in their portfolio include Aztlan Global Stock Selection DM SMID ETF (AZTD), Alger Weatherbie Enduring Growth ETF (AWEG), Janus Henderson Small Cap Growth Alpha ETF (JSML), SPDR S&P Health Care Services ETF (XHS), BNY Mellon Women's Opportunities ETF (BKWO), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), AdvisorShares Alpha DNA Equity Sentiment ETF (SENT) and Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD). What guidance has Progyny issued on next quarter's earnings? Progyny updated its second quarter 2024 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of 0.390-0.410 for the period, compared to the consensus EPS estimate of 0.180. The company issued revenue guidance of $300.0 million-$310.0 million, compared to the consensus revenue estimate of $335.8 million. What is David Schlanger's approval rating as Progyny's CEO? 25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among the company's employees. What other stocks do shareholders of Progyny own? Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), Home Depot (HD), Advanced Micro Devices (AMD). When did Progyny IPO? Progyny (PGNY) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers. Who are Progyny's major shareholders? Progyny's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.65%), Clearbridge Investments LLC (3.64%), Jennison Associates LLC (2.70%), Riverbridge Partners LLC (2.08%), Principal Financial Group Inc. (1.46%) and Baillie Gifford & Co. (1.16%). Insiders that own company stock include Cheryl Scott, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Kevin K Gordon, Mark S Livingston, Michael E Sturmer, Norman Payson, Peter Anevski, Robert Michael Floyd and Tpg Gp A, Llc. View institutional ownership trends. How do I buy shares of Progyny? Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PGNY) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored(Free Workshop) Advanced “bug-out bag” hacks!“Do you have a ‘bug-out bag’ (survival kit) ready to grab-and-go when a disaster or other crisis strikes?” ...Warrior Life | SponsoredSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Progyny, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Progyny With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.